Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
- Celgene Launches Japan PI for Pleiotropic Pathway Modifier
September 29, 2015
- Chugai to Create New Post to Gear Up for HTA Introduction
September 28, 2015
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- Achieving New Share Target for Generics Will Be “Quite Difficult”: Hengrui Japan President
September 25, 2015
- Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
- Novartis Files Afinitor for GI and Lung Neuroendocrine Tumors in Japan
September 24, 2015
- Amgen Gets Rights to MTPC’s Dyslipidemia Drug after Dezima Acquisition
September 18, 2015
- Chugai Seeks Cervical Cancer Indication for Avastin
September 18, 2015
- Opdivo Gets Breakthrough Therapy Designation for RCC
September 18, 2015
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…